Description
In a new era of heightened scrutiny, there is one place where you can learn how to reduce the risk of massive fines, litigation costs, misconduct charges, guilty pleas, negative publicity and more. Back in its 10th national installment, Fraud & Abuse in the Sale and Marketing of Drugs will provide you with the most-up-to-date insights into how to reshape your compliance programs to reflect changes in enforcement priorities while also developing corporate policies that will protect against future fraud claims.
Never before have pharmaceutical companies been so pressured by issues arising simultaneously on the state, national and international level. At this uniquely trying time, day-to-day activities can become the focus of inquiries by members of Congress, investigations by federal and/or state prosecutors, and whistleblower claims. In addition, companies must keep track of legislative initiatives seeking broader industry disclosures and comply with new reporting requirements.
As such, companies must now focus on revising internal practices to meet the new standards that have been set, taking extra precautions to ensure that they are minimizing the risk of being accused of engaging in activities that constitute off label promotion or violate the False Claims Act or the FCPA.
Featuring a faculty comprised of the most expert in-house and outside counsel speakers in the industry, this conference will provide you with a sophisticated and comprehensive understanding of the most difficult and costly issues facing companies today, along with practical strategies for tackling these challenges.
A recurring highlight of this event is the government enforcement panel where you will hear straight from government enforcers about the most current enforcement priorities, triggers, and targets.
